Global pharmaceutical company Eli Lilly (NYSE:LLY) reported revenue ahead of Wall Streets expectations in Q3 CY2025, with ...

With a market cap of around $730 billion, Eli Lilly (NYSE: LLY) is one of the largest pharmaceutical companies on planet ...

Eli Lilly (LLY) stock rises after reporting that sales of its weight-loss drugs more than doubled in the third quarter. The ...

What Happened? Shares of global pharmaceutical company Eli Lilly (NYSE:LLY) jumped 3.1% in the morning session after the ...

October 30th is the day when Eli Lilly will report its third-quarter results, including sales of its 'superstars' Zepbound ...

I go over 3 potential catalysts that could drive Eli Lilly's stock price up... or down. Read the full analysis here.

Offers a broad portfolio of pharmaceuticals targeting diabetes, oncology, immunology, neuroscience, and other therapeutic areas; key products include Zepbound ...

Eli Lilly holds the lead position in the weight management market right now. But Viking Therapeutics is working on a ...

Doctors called it “huge for patients,” if true. Patients who’ve struggled to afford the pricey medicines shared hope the price could be reached. Stocks of Novo Nordisk and Eli Lilly fell significantly ...

Eli Lilly stock (NYSE: LLY) is up 7% in a month, warranting investor attention following a key corporate development. Eli ...

See, LLY stock warrants your attention. Why? Because it offers monopoly-like high margins at a discounted price.

Eli Lilly beat Q3 estimates with $7.02 EPS and $17.60 billion revenue, raising full-year guidance as Zepbound and Mounjaro ...